Zina Chatzidimitriadou

Associate, Sidley Austin

Zina advises clients ranging from emerging to leading global companies, primarily in the biotech, pharmaceutical, healthtech/ medical device and food and cosmetics sectors. Her practice covers advising on and litigating in connection to a broad range of UK and EU legal issues, including product approvals, regulatory submissions, clinical development and studies, market access, maximisation of regulatory intellectual property rights and advertising and promotion. Zina's focus is on digital health, companion diagnostics and advanced therapy medicinal products (gene and cell therapies) with a particular interest in the regulatory and reimbursement aspects of novel products, also including an AI element.

Contributed to

1

Coronavirus (COVID-19)—regulatory implications for the UK and European life sciences industry [Archived]

Practice notes

This Practice Note has been archived and is not maintained. It discusses the regulatory implications of the coronavirus (COVID-19) pandemic for the UK and European life sciences industry. It provides guidance as to the response of UK and EU regulators in the areas of clinical trials, inspections and the continuity of supply in medicinal products and medical devices, as well as the postponement of implementation of the Medical Devices Regulation (MDR). It also summarises key research and development (R&D) initiatives at a UK and EU level and European Commission guidance on the collection and transfusion of convalescent COVID-19 plasma.

Life Sciences